NEU 6.41% $15.27 neuren pharmaceuticals limited

Ann: Neuren approaching key milestones in Q4 2019, page-53

  1. 271 Posts.
    lightbulb Created with Sketch. 400
    Sure, when I reread that sentence regarding corporate transactions and torraya it seems like you say - potentially limitless. I admit that is possible. But isn’t that a tad pessimistic? I don’t think that is the intent of this release. Is it not simply an update further to RT’s indication that he was looking forward to giving news in q3 regarding discussions with partners in Europe, Japan, and the US? Those discussions are still being finalised and are unable to be concluded in q3 as previously flagged and the market required an update due to expectation. Is the previously indicated q3 conclusion of discussions with these partners completely off the boil now based on those few words “will continue in q4”? It’s reading a lot into it. It is worth writing to or ring RT about to confirm perhaps? But logically at this stage I think it is a simple update. Love to know what others think there.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.